Als u de informatie op kanker-actueel waardeert wilt u misschien donateur worden van onze Stichting Gezondheid Actueel. Wij zijn ook een ANBI organisatie. Als donateur kunt u korting krijgen op voedingssupplementen bij verschillende bedrijven.

Bij Oriveda krijgen onze donateurs 25% korting op extracten van medicinale paddenstoelen. Nog een reden om donateur te worden als u extracten van medicinale paddenstoelen wilt gaan gebruiken misschien?

30 december 2018: lees ook dit artikel: 

https://kanker-actueel.nl/extracten-van-medicinale-paddenstoelen-worden-ook-in-reguliere-oncologie-meer-en-meer-gezien-als-een-natuurlijke-behandeling-van-verschillende-vormen-van-kanker-blijkt-uit-recente-reviewstudie.html

17 december 2018: lees ook dit artikel: 

https://kanker-actueel.nl/waar-moet-je-op-letten-bij-de-aankoop-van-extracten-van-medicinale-paddenstoelen-hier-wat-richtlijnen.html

1 maart 2018: zie ook dit artikel:  

https://kanker-actueel.nl/champignons-bewerkt-met-speciale-belichting-hebben-daarmee-veel-extra-vitamine-d-en-kunnen-vitamine-d-supplementen-vervangen.html

17 mei 2012: recent is verschenen het abstract van een review studie uit 2012 over de waarde van PSK - polysaccharide K (KRESTIN(®) bij vele vormen van kanker - Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives - waaronder vooral ook bij vormen van spijsverteringskanker, zoals darmkanker, rectumkanker, maagkanker enz.. Zie ook in linkerkolom voor meer artikelen en informatie. Als u hier klikt kunt u het volledige studie rapport van deze review studie gratis inzien.

Hier het abstract van deze studie, onderaan meer algemene informatie en meer studie verwijzingen. In gerelateerde artikelen staan artikelen met meer toegespitste informatie. Raadpleeg wel altijd een goed gekwalificeerd orthomoleculair arts

 Surg Today. 2012 January; 42(1): 8–28.
Published online 2011 December 6. doi:  10.1007/s00595-011-0075-7
PMCID: PMC3253283

Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives

Abstract

The mechanism of action of protein-bound polysaccharide K (PSK; KRESTIN®) involves the following actions: (1) recovery from immunosuppression induced by humoral factors such as transforming growth factor (TGF)-β or as a result of surgery and chemotherapy; (2) activation of antitumor immune responses including maturation of dendritic cells, correction of Th1/Th2 imbalance, and promotion of interleukin-15 production by monocytes; and (3) enhancement of the antitumor effect of chemotherapy by induction of apoptosis and inhibition of metastasis through direct actions on tumor cells. The clinical effectiveness of PSK has been demonstrated for various cancers. In patients with gastric or colorectal cancer, combined use of PSK with postoperative adjuvant chemotherapy prolongs survival, and this effect has been confirmed in multiple meta-analyses. For small-cell lung carcinoma, PSK in conjunction with chemotherapy prolongs the remission period. In addition, PSK has been shown to be effective against various other cancers, reduce the adverse effects of chemotherapy, and improve quality of life. Future studies should examine the effects of PSK under different host immune conditions and tumor properties, elucidate the mechanism of action exhibited in each situation, and identify biomarkers.

26 oktober 2009: Een groot aantal belangrijke studies van effect van PSK geactualiseerd. Zie abstracten hieronder die duidelijk aangeven dat PSK significant beter werkt dan chemo bij darmkanker.   Raadpleeg wel altijd een deskundig arts voor gebruik van medicinale paddestoelen.


Hier via korte omschrijving aantal studies gedaan met PSK en PSP op een rijtje gezet.

Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K. Krestin (PSK). Cancer Treatment Reviews 1984 Jun;11(2):131-55. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. [91 refs].

Alternative Medicine Review. 2000 Feb;5(1):4-27. Ng TB. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). [35 refs].

General Pharmacology. 1998 Jan;30(1):1-4. Kobayashi H, Matsunaga K, Oguchi Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview.

Cancer Epidemiology, Biomarkers & Prevention 1995 Apr-1995 May;4(3):275-81. Kobayashi H, Matsunaga K, Fujii M. PSK as a chemopreventive agent.

Cancer Epidemiology, Biomarkers & Prevention 1993 May-1993 Jun;2(3):271-6. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer.

Diseases of the Colon and Rectum 1992;35(2):123-30. Jong S-C, Donovick R. Antitumor and antiviral substances from fungi.

Advances in Applied Microbiology 1989;34:183-262. Sakagami H, Takeda M. Diverse biological activity of PSK (Krestin), a protein-bound polysaccharide from Coriolus versicolor (Fr.) Quel.:237-45. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. [179 refs].

Current Medicinal Chemistry. 2000 Jul;7(7):715-29. Fisher M, Yang L-X. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.

Anticancer Research 2002;22:1737-54. Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer.

Cancer Chemotherapy & Pharmacology 1997 Jul;40(3):233-8. Maehara Y, Inutsuka S, Takeuchi H, Baba H, Kusumoto H, Sugimachi K. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer.

Cancer Chemotherapy & Pharmacology 1993;33(2):171-5. Kodama Y, Kano T, Tamada R, Kumashiro R, Okamura T, Inokuchi K. Combined effect of prophylactic lymphadenectomy and long term combination chemotherapy for curatively resected carcinoma of the stomach.

Japanese Journal of Surgery 1982;12(4):244-8. Kano T, Kumashiro R, Masuda H, Tamada R, Inokuchi K. Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection.

Japanese Journal of Surgery 1983;13(2):112-6. Kano T, Tamada R, Abe Y, Hiramoto Y, Notsuka T, Shiraishi M, et al. Postoperative long-term cancer chemotherapy (PLCC) extends life-span of non-curatively resected patients with stage IV gastric cancer.

Japanese Journal of Surgery 1982;12(3):201-7. Kano T, Kumashiro R, Tamada R, Kodama Y, Inokuchi K. Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach.

Japanese Journal of Surgery 1981;11(4):291-6. Shibata M, Nezu T, Kanou H, Nagata Y, Kimura T, Takekawa M, et al. Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer.

Cancer Investigation. 2002;20(2):166-73. Munemoto Y, Iida Y, Abe J, Saito H, Fujisawa K, Kasahara Y, et al. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival.

International Journal of Oncology. 2002 Feb;20(2):403-11. Kawa K, Konishi S, Tsujiino G, Mabuchi S. Effects of biological response modifiers on childhood ALL being in remission after chemotherapy.

Biomedicine & Pharmacotherapy 1991;45:113-6. Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, et al. Randomized adjuvant trial to evaluate the addition of Tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.

Cancer 1992;70(10):2475-83. Go P, Chung C-H. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx.

The Journal of International Medical Research 1989;17:141-9. Ohno R, Yamada K, Masaoka T, Ohshima T, Amaki I, Hirota Y, et al. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation.

Cancer Immunology, Immunotherapy 1984;18:149-54. Nagao T, Komatsuda M, Yamauchi K, Nozaki H, Watanabe K, Arimori S. Chemoimmunotherapy with Krestin in acute leukemia.

Tokai Journal of Experimental & Clinical Medicine 1981;6(2):141-6. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer.

The Lancet 1994;343:1122-6. Iino Y, Yokoe T, Maemura M, Horiguchi J, Takei H, Ohwada S, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer.

Anticancer Research 1995;15:2907-12. Hayakawa K, Mitsuhashi N, Saito Y, Takahashi M, Katano S, Shiojima K, et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer.

Anticancer Research 1993;13:1815-20. Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer.

Cancer Immunology, Immunotherapy 1990;31:261-8. Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M, et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.

Anticancer Research. 1997 Jul-Aug;17(4A):2815-8. Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years.

Japanese Journal of Surgery 1988;18(6):681-6. Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M. Possible predictive markers of immunotherapy in esophageal cancer: Retrospective analysis of a randomized study.

Cancer Investigation 1995;13(4):363-9. Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M, et al. Immunotherapy for esophageal cancer: A randomized trial in combination with radiotherapy and radiochemotherapy.

American Journal of Clinical Oncology 1995;18(3):216-22. Chung C-H, Go P, Chang K-H. PSK immunotherapy in cancer patients - a preliminary report.

Chinese Journal of Microbiology and Immunology 1987;20:210-6. Toge T, Yamaguchi Y. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count.

Oncology Reports. 2000 Sep-2000 Oct;7(5):1157-61. Saji S, Sakamoto J, Teramukai S, Kunieda K, Sugiyama Y, Ohashi Y, et al. Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer.

Surgery Today. 1999;29(6):504-10. Ogoshi K, Miyaji M, Nakamura K, Kondoh Y, Makuuchi H, Tajima T. Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute-phase reactants.

Cancer Immunology, Immunotherapy. 1998 Mar;46(1):14-20. Ogoshi K, Tajima T, Mitomi T, Makuuchi H, Tsuji K. HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer.

Cancer Immunology, Immunotherapy. 1997 Oct;45(1):53-9. Takahashi H, Okamoto M, Saito A, Suzuki T. Clinical experience of PSK to head and neck cancer; with special reference to combination with irradiation. Gan Kagakuryoho 1980;7(3):489-95. Kato M, Hirose K, Hakozaki M, Ohno M, Saito Y, Izutani R, et al. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide.

Cancer Immunology, Immunotherapy 1995;40:152-6. Nio Y, Tsubono M, Tseng C-C, Morimoto H, Kawabata K, Masai Y, et al. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer.

Biotherapy 1992;4:117-28. Katoh R, Takenoshita S, Shimizu Y, Tanaka S, Yajima Y, Nagamachi Y. Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer.

Anticancer Research. 1997 Sep-1997 Oct;17(5B):3787-92. Kariya K, Nakamura K, Nomoto K, Matama S, Saigenji K. Mimicking of superoxide dismutase activity by protein-bound polysaccharide of Coriolus versicolor QUEL, and oxidative stress relief for cancer patients.

Molecular Biotherapy 1992 Mar;4(1):40-6. Anai H, Sakaguchi Y, Emi Y, Kohnoe S, Maehara Y, Sugimachi K. A protein-bound polysaccharide immunomodulator, PSK, does not suppress the conversion from 1-(2-tetrahydrofuryl)-5-fluorouracil to 5-fluorouracil in patients with gastric cancer.

Anti-Cancer Drugs 1991 Jun;2(3):275-8. Inoue M, Kawa K, Tawa A, Yumura K, Konishi S, Fujinami A, et al. Effects of biological response modifiers on childhood ALL being in remission after chemotherapy. Biotherapy 1988;2:563.


Plaats een reactie ...

Reageer op "Algemeen: Nog een aantal studies met PSK en PSP - stofje uit medicinale paddestoelen bij elkaar gezet."


Gerelateerde artikelen